05/11/2026
A consistent cell source is only the starting point. The real challenge is translating cellular potential into demonstrated clinical benefit while maintaining product quality throughout manufacturing.
Drawing on a case study of iPSC-derived MSC clinical programmes, our latest article examines the lessons behind the gap between promising early findings and clinical outcomes.
We explore why cell sourcing, mechanism of action, functional potency, clinical evidence and manufacturing process control must be considered as interconnected elements of cell therapy development.
As the industry moves towards larger-scale production, the focus must extend beyond cell expansion to building processes that consistently deliver well-characterised therapeutic products.
đź“„ Read the full article here: https://en.cytoniche.com/notes_detail/33.html